FDA accepts BLA filing of Aimmune Therapeutics’ AR101 for peanut allergy
Aimmune Therapeutics announced that the Biologics License Application for AR101 has been accepted for review by the FDA. Aimmune is developing AR101 as a treatment to reduce the risk of anaphylaxis following accidental exposure to peanut. March 18, 2019